Article Information
History
- January 24, 2022.
Article Versions
- You are currently viewing Version 1 of this article (January 24, 2022 - 22:30).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Anton Barchuk1,5,6,✉,
- Anna Bulina1,
- Mikhail Cherkashin2,
- Natalia Berezina2,
- Tatyana Rakova2,
- Darya Kuplevatskaya2,
- Oksana Stanevich1,4,
- Dmitriy Skougarevskiy1 and
- Artemiy Okhotin3,4
- 1Institute for Interdisciplinary Health Research, European University at St. Petersburg, Shpalernaya Ulitsa 1, St. Petersburg, Russia, 191187
- 2Medical Institute named after Berezin Sergey, Esenina Ulitsa 2-3a, St. Petersburg, Russia, 194354
- 3Tarusa Hospital, Karla Libknekhta Ulitsa 16, Tarusa, Russia, 249100
- 4ITMO University, St. Petersburg, Russia, 197101
- 5NN Petrov National Research Medical Centre of Oncology, Pesochny, Leningradskaya Ulitsa 68, St. Petersburg, Russia, 197758
- 6Health Sciences, Faculty of Social Sciences, Tampere University, Arvo Ylpön katu 34, Tampere, Finland, 33520
- ↵✉Correspondence: Anton Barchuk, email: abarchuk{at}eu.spb.ru
Posted January 24, 2022.
COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 Delta variant infection: a population-based case-control study in St. Petersburg, Russia
